The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

NICE backs obinutuzumab plus bendamustine chemotherapy for patients with follicular lymphoma

May 14, 2020

The United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has recommended National Health Service (NHS) funding for obinutuzumab in combination with bendamustine chemotherapy for patients with follicular lymphoma (FL). Patients with FL who have not responded to, or who have progressed up to six months after rituximab or rituximab-containing treatment, will now be able to receive the combination via the NHS, as opposed to funding from the Cancer Drugs Fund.

An updated analysisof the GADOLIN study, which compared obinutuzumab plus bendamustine versusbendamustine alone, found the combination regimen provided a progression-free survival benefit over bendamustine monotherapy in patients with indolent non-Hodgkin lymphoma, including FL.

  1. National Institute for Health and Clinical Excellence (NICE). Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. https://www.nice.org.uk/guidance/ta629/chapter/1-Recommendations. Published May 13, 2020. Accessed May 13, 2020.